Walleye Capital LLC Reduces Holdings in IDEAYA Biosciences, Inc. (NASDAQ:IDYA)

Walleye Capital LLC reduced its position in IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report) by 84.9% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 21,312 shares of the company's stock after selling 119,859 shares during the period. Walleye Capital LLC's holdings in IDEAYA Biosciences were worth $548,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also recently added to or reduced their stakes in the company. XTX Topco Ltd raised its stake in shares of IDEAYA Biosciences by 64.3% during the 4th quarter. XTX Topco Ltd now owns 12,679 shares of the company's stock worth $326,000 after buying an additional 4,960 shares during the period. Mariner LLC grew its holdings in shares of IDEAYA Biosciences by 9.8% during the fourth quarter. Mariner LLC now owns 9,775 shares of the company's stock worth $251,000 after buying an additional 869 shares in the last quarter. Barclays PLC grew its stake in IDEAYA Biosciences by 9.7% during the 4th quarter. Barclays PLC now owns 198,756 shares of the company's stock valued at $5,108,000 after acquiring an additional 17,586 shares in the last quarter. Raymond James Financial Inc. acquired a new stake in shares of IDEAYA Biosciences in the fourth quarter valued at approximately $431,000. Finally, Renaissance Technologies LLC raised its holdings in shares of IDEAYA Biosciences by 66.9% during the 4th quarter. Renaissance Technologies LLC now owns 284,267 shares of the company's stock worth $7,306,000 after acquiring an additional 113,902 shares during the period. 98.29% of the stock is owned by hedge funds and other institutional investors.

IDEAYA Biosciences Price Performance

Shares of IDEAYA Biosciences stock traded up $0.75 on Monday, reaching $19.75. 2,221,660 shares of the company were exchanged, compared to its average volume of 959,881. The stock's 50 day moving average price is $17.98 and its 200-day moving average price is $23.29. The company has a market cap of $1.73 billion, a P/E ratio of -5.98 and a beta of 0.51. IDEAYA Biosciences, Inc. has a 1-year low of $13.45 and a 1-year high of $44.42.

IDEAYA Biosciences (NASDAQ:IDYA - Get Free Report) last announced its quarterly earnings data on Thursday, February 13th. The company reported ($1.49) EPS for the quarter, missing analysts' consensus estimates of ($0.67) by ($0.82). The business had revenue of $7.00 million for the quarter, compared to the consensus estimate of $7.00 million. On average, research analysts predict that IDEAYA Biosciences, Inc. will post -3.07 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on the company. Stephens reaffirmed an "overweight" rating and issued a $50.00 price target on shares of IDEAYA Biosciences in a research note on Friday, February 14th. Cantor Fitzgerald restated an "overweight" rating on shares of IDEAYA Biosciences in a report on Monday, January 13th. Finally, Royal Bank of Canada reiterated an "outperform" rating and issued a $61.00 target price on shares of IDEAYA Biosciences in a report on Wednesday, January 15th. Two analysts have rated the stock with a hold rating, twelve have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $53.58.

About IDEAYA Biosciences

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.